Alimentary Pharmacology & Therapeutics最新文献

Editorial: LAMP Lights the Way-A Pragmatic Case for NUDT15 Screening Across Diverse Populations. 社论：LAMP照亮道路——在不同人群中进行NUDT15筛查的实用案例。

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-25 DOI: 10.1111/apt.70260

Swarup A V Shah,Devendra Desai

引用次数: 0

Editorial: Polypharmacy in MASLD-An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis. 社论：masld的多重用药——一种被忽视的影响女性和肝硬化患者的流行病。

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-25 DOI: 10.1111/apt.70307

Mary Yue Wang,Terry Cheuk-Fung Yip

引用次数: 0

Editorial: LAMP Lights the Way-A Pragmatic Case for NUDT15 Screening Across Diverse Populations-Authors' Reply. 社论：LAMP照亮道路——在不同人群中进行NUDT15筛查的实用案例——作者回复。

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-25 DOI: 10.1111/apt.70289

Chris Roberts,James R Goodhand,Tariq Ahmad

引用次数: 0

Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi-Centre Propensity Score Matched Analysis. 无炎症性肠病的原发性硬化性胆管炎增加结直肠癌的风险：多中心倾向评分匹配分析

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-24 DOI: 10.1111/apt.70303

Saqr Alsakarneh,Razan Aburumman,Mohammad Bilal,Adam S Faye,Jana G Hashash,Aasma Shaukat

{"title":"Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi-Centre Propensity Score Matched Analysis.","authors":"Saqr Alsakarneh,Razan Aburumman,Mohammad Bilal,Adam S Faye,Jana G Hashash,Aasma Shaukat","doi":"10.1111/apt.70303","DOIUrl":"https://doi.org/10.1111/apt.70303","url":null,"abstract":"INTRODUCTIONPatients with primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC). However, the risk of CRC in patients with PSC without IBD remains uncertain. We aimed to evaluate the risk of CRC in patients with PSC without a history of IBD using a large national database.METHODSWe conducted a retrospective cohort study using the TriNetX database to identify patients ≥ 18 years with PSC. Patients were then divided into two groups, PSC with IBD (PSC-IBD cohort) and PSC without IBD (PSC non-IBD cohort), and were matched with patients without a history of PSC or IBD (non-PSC/non-IBD group) by using 1:1 propensity score matching. The primary outcome was the risk of first diagnosis of CRC. With censoring applied, Kaplan-Meier analysis with hazard ratios (HRs) and 95% CIs was used to compare time-to-event rates at daily time intervals.RESULTSPSC patients without IBD were at increased risk of CRC compared to the non-PSC/IBD cohort (aHR = 2.91; 95% CI: 1.6-6.0). Patients with PSC and IBD exhibited a higher risk of CRC (aHR = 6.5; 95% CI: 3.78-11.2), especially among the UC cohort (aHR = 6.3; 95% CI: 3.2-12.4). Patients with PSC were at increased risk of various gastrointestinal malignancies (aHR = 10.5; 95% CI: 7.3-15; p < 0.0001), including hepatobiliary cancers, pancreatic cancer, and hepatocellular carcinoma.DISCUSSIONOur findings provide real-world evidence that PSC is an independent risk factor for colorectal cancer, even in the absence of concomitant IBD. These results support the need for further research to determine whether patients with isolated PSC may benefit from tailored CRC surveillance strategies.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"27 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series 研究交流：Upadacitinib联合英夫利昔单抗、Risankizumab、Ustekinumab或Vedolizumab治疗难治性克罗恩病：描述性病例系列

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-24 DOI: 10.1111/apt.70298

Rahul S. Dalal, Lindsay M. Clarke, Heidy J. Cabral, Alexander D. Carlin, Grace B. Hardwick, Jessica R. Allegretti

引用次数: 0

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. 特利加压素治疗后肝肾综合征-急性肾损伤患者的心动过缓和其他心律失常：三个北美III期临床研究的汇总分析

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-24 DOI: 10.1111/apt.70297

Jasmohan S Bajaj,Paul Kwo,Stephen Chris Pappas,Jacqueline G O'Leary,Khurram Jamil,Sanaz Cardoza,Florence Wong

{"title":"Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies.","authors":"Jasmohan S Bajaj,Paul Kwo,Stephen Chris Pappas,Jacqueline G O'Leary,Khurram Jamil,Sanaz Cardoza,Florence Wong","doi":"10.1111/apt.70297","DOIUrl":"https://doi.org/10.1111/apt.70297","url":null,"abstract":"BACKGROUNDTerlipressin is the FDA-approved systemic vasoconstrictor therapy for hepatorenal syndrome-acute kidney injury (HRS-AKI)-a rapidly progressive renal failure occurring in patients with decompensated cirrhosis and ascites. Bradycardia, a known effect of terlipressin, as well as other arrhythmias, has previously been reported in terlipressin-treated patients.AIMTo assess terlipressin-related cardiac adverse events (AEs) in patients with HRS-AKI.METHODSThree North American-centric Phase III, randomised, placebo-controlled studies (OT-0401, REVERSE, CONFIRM) were pooled in the largest-to-date prospective database. Cardiac AEs were reported by the investigators for each trial and retrospectively analysed.RESULTSBradycardia was the only cardiac AE reported more frequently in terlipressin-treated patients compared with placebo (6.3% [22/349] vs. 0.8% [2/249]). In the terlipressin group, no bradycardia AEs were serious, 4.5% (1/22) of patients required a dose interruption, 9.1% (2/22) required a dose reduction, and none discontinued treatment due to bradycardia. The incidences of other arrhythmia AEs were similar in both treatment groups (terlipressin: 7.4% [26/349]; placebo 8.8% [22/249]). The incidence of atrial fibrillation serious AEs (SAEs) was low (terlipressin: 0.9% [3/349]; placebo: 1.6% [4/249]). There were no AE reports of torsades de pointes, while a QT interval prolongation was reported in two patients.CONCLUSIONSIn a pooled analysis, bradycardia was observed in 6% of terlipressin-treated patients but rarely required a dose interruption or reduction. Arrhythmia SAE incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin administration.TRIAL REGISTRATIONOT-0401: NCT00089570, REVERSE: NCT01143246 and CONFIRM: NCT02770716.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"19 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia-Authors' Reply. 信：幽门螺旋杆菌感染可能构成反流性疾病和结肠肿瘤的危险因素——作者回复。

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-23 DOI: 10.1111/apt.70305

Amnon Sonnenberg,Anna M Buchner,Ruth Kohen

引用次数: 0

Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia. 信：幽门螺杆菌感染可能构成反流疾病和结肠肿瘤的危险因素。

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-23 DOI: 10.1111/apt.70299

Jannis Kountouras,Christos Zavos,Elisabeth Vardaka,Evangelos Kazakos

引用次数: 0

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD 持续酗酒史与晚期肝纤维化和全因死亡率相关

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-22 DOI: 10.1111/apt.70286

Zhe‐Kun Xiong, Ru‐Tao Lin, Bi‐Wei Chen, Xin Xin, Tao‐Ying Deng, Qin‐Mei Sun, Yi‐Yang Hu, Li‐Ming Gan, Qin Feng

{"title":"Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD","authors":"Zhe‐Kun Xiong, Ru‐Tao Lin, Bi‐Wei Chen, Xin Xin, Tao‐Ying Deng, Qin‐Mei Sun, Yi‐Yang Hu, Li‐Ming Gan, Qin Feng","doi":"10.1111/apt.70286","DOIUrl":"https://doi.org/10.1111/apt.70286","url":null,"abstract":"BackgroundMetabolic dysfunction and alcohol‐related liver disease (MetALD) is characterised by the coexistence of metabolic dysfunction and moderate alcohol intake. In this population, the impact of specific drinking patterns and history, particularly persistent binge drinking (PBD) history, on disease severity and prognosis remains unclear.AimTo evaluate the association between a history of PBD and the risks of advanced fibrosis and all‐cause mortality in individuals with MetALD.MethodsWe analysed data from NHANES 1999–2016, including adults with MetALD. PBD is defined as having had a history of drinking ≥ 4 (women) or 5 (men) alcoholic beverages almost every day, based on ALQ150/151 questionnaires. Advanced fibrosis was defined as FIB‐4 > 2.67, and mortality outcomes were obtained from the National Death Index. Multivariable logistic and Cox regression models were used to examine the associations between PBD and both liver fibrosis and all‐cause mortality, adjusting for alcohol intake and other confounders.ResultsAmong 865 individuals with MetALD, 326 (37.7%) reported a history of PBD. Compared to those without PBD, participants with PBD had a higher risk of advanced fibrosis (adjusted OR = 2.23, 95% CI: 1.12–4.45, p = 0.023). PBD was also associated with increased all‐cause mortality (adjusted HR = 1.48, 95% CI: 1.03–2.13, p = 0.035). A higher risk of overnight hospitalisation in PBD supports these findings (adjusted OR = 1.88, 95% CI: 1.15–3.06, p = 0.012).ConclusionPBD history is associated with increased risks of advanced fibrosis and mortality in MetALD. Clinical assessment should include an evaluation of drinking patterns and history, particularly persistent binge drinking.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"98 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144677540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease. 一项有和没有炎症性肠病的国家队列结肠癌手术后的结果

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2025-07-22 DOI: 10.1111/apt.70296

Erik Lundqvist,Karin Westberg,Sol Erika Boman,Ida H Myrberg,Åsa H Everhov,Pär Myrelid,Bengt Glimelius,Anna Martling,Caroline Nordenvall

{"title":"Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease.","authors":"Erik Lundqvist,Karin Westberg,Sol Erika Boman,Ida H Myrberg,Åsa H Everhov,Pär Myrelid,Bengt Glimelius,Anna Martling,Caroline Nordenvall","doi":"10.1111/apt.70296","DOIUrl":"https://doi.org/10.1111/apt.70296","url":null,"abstract":"AIMSTo estimate the impact of inflammatory bowel disease on survival in a national cohort of patients following surgical resection for colon cancer, and to describe the surgical treatment of colon cancer in patients with inflammatory bowel disease.METHODSUsing the Colorectal Cancer Database, we included all patients ≥ 15 years of age with a diagnosis of stages I-III colon cancer treated with curative intent 2007-2021. We used Cox proportional hazards models to compare overall survival, recurrence-free survival and cancer-specific survival between patients with and without inflammatory bowel disease. Multivariable analyses were adjusted for sex, age, date of colon cancer surgery, Charlson Comorbidity Index and primary sclerosing cholangitis.RESULTSAmong 35,640 patients with colon cancer, 675 (1.9%) had inflammatory bowel disease. Median age at colon cancer diagnosis was 68 years in patients with inflammatory bowel disease and 75 in those without; proportions of male sex were 55% and 49%, respectively. In patients with inflammatory bowel disease, surgical therapy was proctocolectomy in 10%, subtotal colectomy in 29% and segmental resection in 61%. From adjusted analyses, patients with inflammatory bowel disease had worse overall survival (HR = 1.38; 95% CI: 1.21-1.57), recurrence-free survival (HR = 1.33; 95% CI: 1.18-1.50) and cancer-specific survival (HR = 1.46; 95% CI: 1.23-1.73) than patients without.CONCLUSIONInflammatory bowel disease negatively influences the prognosis of colon cancer. Proctocolectomy was performed only in a minority of those with inflammatory bowel disease. Outcomes need to be improved in patients with inflammatory bowel disease developing colon cancer.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"115 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0